戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 odextrin-porphyrinoid assemblies enhance the photodynamic abilities of porphyrinoids, can carry chemo
2 imizes the ISC rate, and thus enables strong photodynamic action only under pathological stimulus (su
3 derivative exhibited exceptionally effective photodynamic activity on a number of tumor cell lines (H
4 ndogenous AhR ligand FICZ displays nanomolar photodynamic activity representing a molecular mechanism
5                                The excellent photodynamic activity resulted from the rigid spatial ar
6                                         High photodynamic activity was observed for hexadeca-cationic
7                     These findings present a photodynamic agent that can be used for both photodynami
8                                              Photodynamic agents have the potential to combine both f
9 Cu2-XTe) nanocubes (NCs) as photothermal and photodynamic agents, leading to significant anticancer a
10  to these features, SPNpd exerts synergistic photodynamic and chemo-therapy, and effectively inhibits
11 e and NIR radiate on at 4 degrees C revealed photodynamic and photothermal as mechanism of cytotoxici
12 struction of brain tumor by a combination of photodynamic and sonodynamic therapy.
13  and ultrafast experimental studies of their photodynamics and discuss the results in comparison to t
14                     Spectral, photophysical, photodynamic, and biological properties of compound were
15 ermore, the trimodal therapy (photothermal-, photodynamic- and chemo-therapy) with SN-NPM demonstrate
16 alue up to 0.91, lambdamax up to 750 nm) and photodynamic anticancer activity.
17 yrrole drives their photoactivity, but their photodynamics are only partially understood.
18 er brush, which comprises a light-responsive photodynamic backbone grafted with poly(ethylene glycol)
19                  Experiments on image-guided photodynamic cancer ablation show that the therapeutic p
20 -stimulated ion desorption, Coulombic decay, photodynamic cancer therapies, and may yield important i
21         Even though the general mechanism of photodynamic cancer therapy is known, the details and co
22 issues, and delivery of photosensitizers for photodynamic cancer therapy.
23 roach is based on capturing molecules with a photodynamic covalent bond inside microemulsions as nano
24 ated micelles exhibited significant in vitro photodynamic cytotoxicity.
25 ng intravenous PMIL administration, triggers photodynamic damage of tumour cells and microvessels, an
26  Failure to assemble such complexes provoked photodynamic damage through the generation of singlet ox
27  infrared laser irradiation induced vascular photodynamic damage, resulting in enhanced liposomal dox
28 from the introduction of blue light assisted photodynamic diagnostic (PDD).
29 alization and patterning strategy based on a photodynamic disulfide exchange reaction is demonstrated
30 ygen produced not only induced a significant photodynamic effect against HepG2 cells but also trigger
31       Herein, we introduce a novel method of photodynamic effect evaluation through in situ detection
32 pplication of MALDI-TOF MS in evaluating the photodynamic effect of each component in a mixture sampl
33 ncreased the cellular uptake by >60% and the photodynamic effect of hydrophobic porphyrins in vitro c
34 ation times were easily screened to optimize photodynamic effect.
35 ony is a conventional method to evaluate the photodynamic effect.
36 o replace the LB agar colony to evaluate the photodynamic effect.
37                                              Photodynamic effects of various bacteria species, cancer
38 in an inadequate oxygen supply which reduces photodynamic efficacy.
39                               Moreover, high photodynamic efficiency was demonstrated at doses of 150
40           We emphasize the unique feature of photodynamic equilibria, in which population of the stat
41                                  Here we use photodynamic imaging, mass spectrometry, parasite gene d
42  of photodynamic therapy (PDT) and microbial photodynamic inactivation (PDI) in clinical applications
43 photosensitizer-containing ETT to be used in photodynamic inactivation (PDI) to avoid bacteria biofil
44 lted in improved antimicrobial activities in photodynamic inactivation experiments using both Gram-po
45 egular cells was successfully tested via the photodynamic inactivation of a ROS stressed Gram negativ
46                                              Photodynamic inactivation of Leishmania has been shown t
47                                              Photodynamic inactivation of microbial cells using light
48 h the intervention of URO/PC2-medated double-photodynamic inactivation to ascertain its complete loss
49 n HaCaT and primary epidermal keratinocytes, photodynamic induction of apoptosis was elicited by the
50 thout light illumination yet highly enhanced photodynamic inhibition efficacy against Hela cells unde
51 and were consequently the primary targets of photodynamic injury, resulting in predominantly necrotic
52 tion and hence signaling, but the underlying photodynamic mechanisms are not known.
53                         Installation of dual photodynamic mechanisms ensures complete inactivation of
54 tution were targeted and we use a stochastic photodynamic model to numerically simulate the evolution
55 c studies over the years, the details of the photodynamics of bR on the excited state, particularly t
56 ing sequential intermediates for the initial photodynamics of isomerization.
57 gh level of detail achievable in probing the photodynamics of nanosystems using tunable XUV pulses.
58 ral photochemical properties and studied the photodynamics of two model systems in more detail, obser
59 t (UV) radiation potentiates the toxicity of photodynamic PAHs (often leading to mortality).
60 rmonic nanoparticles, as well as release via photodynamic (photooxygenation by singlet oxygen) and ph
61 t preclinical evidence that a subtumoricidal photodynamic priming (PDP) strategy can relieve drug del
62                            In this work, the photodynamic properties of [Au(13)(dppe)(5)Cl(2)](3+) ar
63 emotherapy, immunotherapy, radiotherapy, and photodynamic, sonodynamic, chemodynamic, gene, gas, ioni
64                                         This photodynamic strategy has the advantage of exploiting ho
65                                     In vitro photodynamic studies were conducted on human breast canc
66 ut in lung cancer cells (A549) to test their photodynamic therapeutic (PDT) activity.
67 nowhiskers (TP) as effective bio-imaging and photodynamic therapeutic (PDT) agent for RA theranostics
68 olecules developed for anticancer therapies, photodynamic therapeutic agents have a unique profile.
69 hese visible photons have been combined with photodynamic therapeutic agents preclinically for increa
70 e design guideline for enhancing traditional photodynamic therapeutic efficacy integrated with a cont
71 nd supramolecular strategy greatly boost its photodynamic therapeutic efficiency.
72 n nonmelanoma skin cancer were uncertain for photodynamic therapy (3 trials, 93 participants, risk ra
73 randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously
74 ts of repeated applications of antimicrobial photodynamic therapy (aPDT) adjunctive to scaling and ro
75 ficacy of multiple sessions of antimicrobial photodynamic therapy (aPDT) as an adjunct to surgical pe
76 enkov luminescence imaging and (2) Cherenkov-photodynamic therapy (CR-PDT) on cells could be achieved
77 , 5% imiquimod cream, methyl aminolevulinate photodynamic therapy (MAL-PDT), or 0.015% ingenol mebuta
78 ffect compared with reovirus monotherapy and photodynamic therapy (p=0.042) with 100% cell death obse
79 otic lesions followed by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.
80 ing pigment (methylene blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans
81 ypyridyl complexes show great promise as new photodynamic therapy (PDT) agents.
82  development of 2 therapies: (1) verteporfin photodynamic therapy (PDT) and (2) anti-vascular endothe
83 evice has been developed to perform in vitro photodynamic therapy (PDT) and diagnostic assays for tre
84 e recently contributed to the progression of photodynamic therapy (PDT) and microbial photodynamic in
85 the design of transition metal complexes for photodynamic therapy (PDT) and photoactivated chemothera
86 ed with various therapy strategies including photodynamic therapy (PDT) and photothermal therapy (PTT
87 antigen presentation by enabling immunogenic photodynamic therapy (PDT) and promoting the maturation
88                           The combination of photodynamic therapy (PDT) and radiation therapy (RT) mo
89 um behavior, leading to efficient probes for photodynamic therapy (PDT) and stochastic optical recons
90 f increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photo
91 namic therapy (SDT), which is different from photodynamic therapy (PDT) by the use of highly penetrat
92                                              Photodynamic therapy (PDT) can destroy local tumors and
93                                              Photodynamic therapy (PDT) efficacy is limited by the ve
94 neration and exhibits significantly enhanced photodynamic therapy (PDT) efficacy on two colon cancer
95             Moreover, it could be shown that photodynamic therapy (PDT) elevates antitumor immune res
96 vitro, including both chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer.
97                           The utilization of photodynamic therapy (PDT) for the treatment of various
98                                              Photodynamic therapy (PDT) has been applied in cancer tr
99                              In recent years photodynamic therapy (PDT) has received widespread atten
100                                              Photodynamic therapy (PDT) holds great promise for cance
101                            The viable use of photodynamic therapy (PDT) in cancer therapy has never b
102 herapy in ancient texts and the discovery of photodynamic therapy (PDT) in the early 1900s, the landm
103                Continuous irradiation during photodynamic therapy (PDT) inevitably induces tumor hypo
104                                              Photodynamic therapy (PDT) is a clinically approved anti
105                                              Photodynamic therapy (PDT) is a clinically approved ther
106                                              Photodynamic therapy (PDT) is a light-based treatment mo
107                                              Photodynamic therapy (PDT) is a new strategy for treatin
108                                              Photodynamic therapy (PDT) is a promising cancer treatme
109                                              Photodynamic therapy (PDT) is an approved modality for t
110                                              Photodynamic therapy (PDT) is an effective and cosmetica
111                                              Photodynamic therapy (PDT) is an efficacious treatment f
112                                              Photodynamic therapy (PDT) is an important cancer treatm
113                                              Photodynamic therapy (PDT) is an important clinically re
114 reatment of hypoxic tumors, oxygen-dependent photodynamic therapy (PDT) is considerably limited.
115                                              Photodynamic therapy (PDT) is widely used to treat diver
116  great potential as nanophotosensitizers for photodynamic therapy (PDT) owing to their high photosens
117 he resulting RB-C(KLAKLAK)(2) conjugate as a photodynamic therapy (PDT) sensitizer.
118 clinically approved intervention for cancer, photodynamic therapy (PDT) still suffers from limitation
119                                     Although photodynamic therapy (PDT) takes advantage of the spatia
120 are employed to deliver photosensitizers for photodynamic therapy (PDT) through the enhanced penetrat
121 orescence for image-guided surgery (IGS) and photodynamic therapy (PDT) to resect and ablate cancer c
122      These vulnerable cells are subjected to photodynamic therapy (PDT) treatment in the presence of
123            Furthermore, immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors t
124 e entrapped agents that harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that
125 racellular localization and cell response to photodynamic therapy (PDT) were analyzed in MCF10A norma
126 d visual outcomes using combination standard photodynamic therapy (PDT) with intravitreal ranibizumab
127 integration of fluorescence imaging (FL) and photodynamic therapy (PDT) with positron emission tomogr
128                                              Photodynamic therapy (PDT) with protoporphyrin IX (PpIX)
129 nstrate that benzoporphyrin derivative-based photodynamic therapy (PDT), a photochemical cytotoxic mo
130                                              Photodynamic therapy (PDT), a treatment that uses a phot
131 f cancer and dermatological diseases through photodynamic therapy (PDT), and advanced materials for e
132 , 0.09, and 0.07 LogMAR in the no-treatment, photodynamic therapy (PDT), bevacizumab, and ranibizumab
133 rossing (ISC) are highly promising for smart photodynamic therapy (PDT), but achieving this goal rema
134 rates cytotoxic singlet oxygen ((1)O(2)) for photodynamic therapy (PDT), but also triggers a spontane
135                                           In photodynamic therapy (PDT), cells are impregnated with a
136 additional limitations of porphyrin-mediated photodynamic therapy (PDT), including low depths of tiss
137  each clinical treatment tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by contro
138       In order to promote the development of photodynamic therapy (PDT), undesired side effects like
139 ptake of photosensitizers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma m
140                                              Photodynamic therapy (PDT), wherein light sensitive non-
141  intratumoral near-infrared (NIR) two-photon photodynamic therapy (PDT).
142 injections with bevacizumab; ranibizumab; or photodynamic therapy (PDT).
143 ent protoporphyrin IX (PPIX) accumulation in photodynamic therapy (PDT).
144 et oxygen ((1) O2 ) is of great interest for photodynamic therapy (PDT).
145 ce lifetime microscopy (2PLM) and two-photon photodynamic therapy (PDT).
146 ture-activity relationships for their use in photodynamic therapy (PDT).
147 CP@pyrolipid) for effective chemotherapy and photodynamic therapy (PDT).
148 available and urgently desired for antitumor photodynamic therapy (PDT).
149 ing because (1)O2 plays an important role in photodynamic therapy (PDT).
150 or as the shell for potential application in photodynamic therapy (PDT).
151 thus may hold promise as photosensitizers in photodynamic therapy (PDT).
152 l process for fundamental photochemistry and photodynamic therapy (PDT).
153 age biological tissue, which is exploited in photodynamic therapy (PDT).
154  spatially-targeted cytotoxic therapy called photodynamic therapy (PDT).
155  MRI contrasting agents, and sensitizers for photodynamic therapy (PDT); and more recently as models
156 vely killing beta-cells by receptor-targeted photodynamic therapy (rtPDT) with exendin-4-IRDye700DX,
157 vitreal anti-VEGF injection; (3) verteporfin photodynamic therapy (vPDT); or (4) laser photocoagulati
158 xamine the hypothesis that vascular-targeted photodynamic therapy (VTP) with WST11 and clinically rel
159                                X-ray-induced photodynamic therapy (X-PDT) combines both the advantage
160 ine) and their applications in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.
161  to achieve efficient low-dose X-ray-induced photodynamic therapy (X-PDT) with negligible side effect
162  therapy and the other half treated with AWL photodynamic therapy 1 week apart and randomly allocated
163 l prodrug valacyclovir and the peptide-based photodynamic therapy agent, 5-aminolevulinic acid.
164 bial and antiviral agents, anticancer drugs, photodynamic therapy agents, radiotherapy agents and bio
165 y assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveill
166 e findings may help to alleviate pain during photodynamic therapy and also allow for disease modifica
167                                              Photodynamic therapy and anti-VEGF drug development occu
168 ffectiveness and adverse effects of daylight photodynamic therapy and artificial white light (AWL) LE
169 e optogenetic control over neurons, targeted photodynamic therapy and deep tissue imaging.
170 photodynamic agent that can be used for both photodynamic therapy and image-guided surgery, allowing
171                             By chemotherapy, photodynamic therapy and immunotherapy gathering, the tr
172 ence for technologies including bio-imaging, photodynamic therapy and organic light-emitting diodes.
173 ies based on oxygen free radicals, including photodynamic therapy and radiotherapy, have emerged as p
174                           The combination of photodynamic therapy and sonodynamic therapy both in vit
175                           The combination of photodynamic therapy and sonodynamic therapy strongly af
176 ad half of their scalp treated with daylight photodynamic therapy and the other half treated with AWL
177 ent singlet-oxygen generation with potential photodynamic therapy application as demonstrated by in v
178                  Oncolytic viral therapy and photodynamic therapy are potential therapies for inopera
179 ession in cancer cells and susceptibility to photodynamic therapy based on their increased ability to
180 ood coloring agent and a photosensitizer for photodynamic therapy because of its antioxidant properti
181 atoses (AKs) is as effective as conventional photodynamic therapy but has the advantage of being almo
182 e ROS not only directly kills tumor cells by photodynamic therapy but stimulates the dimeric paclitax
183 er enabled the realization of self-amplified photodynamic therapy by the regulation of Ppa release us
184                                              Photodynamic therapy combining nanotechnology has shown
185                        Here we demonstrate a photodynamic therapy construct that integrates both a cy
186         Rose bengal- and riboflavin-mediated photodynamic therapy demonstrated complete growth inhibi
187  imaging and synergetic photothermal therapy/photodynamic therapy derived from the porphyrin-like moi
188 osensitizers into nanostructures can improve photodynamic therapy efficacy and the safety profile of
189 re to sunlight and other patients undergoing photodynamic therapy experience similar pain, which can
190 e variety of potential applications, such as photodynamic therapy for accelerated drug screening, mag
191 therapy and artificial white light (AWL) LED photodynamic therapy for the treatment of AKs on the for
192 eporfin (VP), a light-activated drug used in photodynamic therapy for the treatment of choroidal neov
193 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 20
194       101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biops
195 tatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active su
196 rious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 pa
197                       Methyl aminolevulinate photodynamic therapy has been effective in 1 case but in
198                             The non-invasive photodynamic therapy has been limited to treat superfici
199                     The combinational chemo- photodynamic therapy heavily suppresses tumor growth and
200                              The Microneedle Photodynamic Therapy II (MNPDT-II) study was a randomize
201 lar endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemot
202 o examine the responses to vascular-targeted photodynamic therapy in mice with subcutaneous xenograft
203 TERPRETATION: Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for
204               Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for
205                                 Furthermore, photodynamic therapy is used to initiate the inflammator
206                                              Photodynamic therapy may be an effective therapeutic opt
207                                              Photodynamic therapy may cause pain at the treatment sit
208 bles can act as ideal miniature reactors for photodynamic therapy of cancer cells.
209 frared light, which has great implication in photodynamic therapy of deep-tissue cancers.
210 omedical applications is exemplified here as photodynamic therapy of malignancies.
211 l CPs are efficient photosensitizers for the photodynamic therapy of ras-driven cancers.
212 croneedles could be a promising approach for photodynamic therapy of skin tumors.
213 ng-guided synergistic radio-/X-ray inducible photodynamic therapy of tumors is reported.
214 bined with protoporphyrin IX (PpIX)-mediated photodynamic therapy on a variety of human pancreatic ca
215                                              Photodynamic therapy regimens, which use light-activated
216 es applications in bioimaging and diagnosis, photodynamic therapy regimes, in addition to photovoltai
217                  Reovirus with PpIX-mediated photodynamic therapy resulted in a significantly increas
218 tionic and anionic phthalocyanines (Pcs) for photodynamic therapy suggest systematically significant
219                                              Photodynamic therapy that uses photosensitizers which on
220 hogonal reactions as an original strategy in photodynamic therapy to achieve conditional phototoxicit
221 s oncolytic viral therapy with PpIX-mediated photodynamic therapy to treat pancreatic cancer.
222                                              Photodynamic therapy using an AWL source was as effectiv
223                                              Photodynamic therapy using porfimer (P-PDT) improves pal
224                                     Daylight photodynamic therapy using topical methyl 5-aminolevulin
225 anic framework, Zr-TBB, for highly effective photodynamic therapy via both type I and type II mechani
226          The effect of adding reovirus after photodynamic therapy was also assessed.
227             Next, the potential of SCPNs for photodynamic therapy was evaluated.
228         Their photosensitizing potential for photodynamic therapy was investigated in an in vitro mod
229                    The potential of PPIX for photodynamic therapy was tested in vivo.
230                            Vascular-targeted photodynamic therapy was well tolerated.
231 ects of reovirus combined with PpIX-mediated photodynamic therapy were analysed in methylthiazoltetra
232                            Laser therapy and photodynamic therapy were not applicable due to the exte
233                         Anti-VEGF agents and photodynamic therapy were the only interventions identif
234 in rare diseases, such as porphyrias, and in photodynamic therapy where short-term toxicity is intend
235 itization represents a promising approach in photodynamic therapy where the design of the active phot
236  photothermal therapy and porphyrin-mediated photodynamic therapy which results in complete tumor eli
237               Chemophototherapy (CPT) merges photodynamic therapy with chemotherapy and can substanti
238                                              Photodynamic therapy with microneedle pretreatment at a
239                                              Photodynamic therapy with the construct was successful i
240                                              Photodynamic therapy with verteporfin is an effective ou
241 nor light-induced medicinal chemistry (e.g., photodynamic therapy) are covered, even if metal complex
242                            Vascular-targeted photodynamic therapy, a novel tissue-preserving treatmen
243 ing oxidant production by transition metals, photodynamic therapy, activated macrophages, and platele
244 emonstrates a highly promising new agent for photodynamic therapy, and attracts attention to photosta
245 peutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiothe
246 re interesting for model enzymes, catalysis, photodynamic therapy, and electron transfer.
247 mor hypoxia for enhancement of chemotherapy, photodynamic therapy, and immunotherapy, either individu
248 al in coordination chemistry, anion sensing, photodynamic therapy, and optoelectronics.
249 ns, including light-triggered drug delivery, photodynamic therapy, and photocatalysis.
250 plications, in particular, for optogenetics, photodynamic therapy, and photochemistry.
251 f natural systems and integral components of photodynamic therapy, but their utilization is compromis
252 cations, including therapeutic (photothermal/photodynamic therapy, chemotherapy and synergistic thera
253 is, including cryosurgery, ingenol mebutate, photodynamic therapy, colchicine, and 5-fluorouracil.
254 as photosynthesis, vision, photolithography, photodynamic therapy, etc., is yet to become a common to
255 on of photosensitizers is a key component of photodynamic therapy, exogenous photothermal contrast ag
256  for phototherapeutic interventions, such as photodynamic therapy, has transformed medicine and biolo
257  photodynamic therapy, named X-ray inducible photodynamic therapy, holds tremendous promise due to a
258                                     Daylight photodynamic therapy, however, requires dry and warm wea
259                                              Photodynamic therapy, in which malignant tissue is kille
260 of X-rays instead of UV/Vis light to trigger photodynamic therapy, named X-ray inducible photodynamic
261 pecific interventions (acitretin, imiquimod, photodynamic therapy, nicotinamide, topical diclofenac,
262 radiotherapy with chemotherapy, gas therapy, photodynamic therapy, or immunotherapy.
263 uorescent probes and sensors, photouncaging, photodynamic therapy, or singlet-oxygen detection.
264  addition, light activation has potential in photodynamic therapy, photothermal therapy, radiotherapy
265 , which is used as an antimicrobial agent in photodynamic therapy, potentiates tellurite toxicity.
266 gated as cytotoxic agents and inhibitors, in photodynamic therapy, radiation therapy, drug/gene deliv
267 d radical ions (Type I reaction); whereas in photodynamic therapy, the tumor destruction is mainly ca
268 , photoreformation, photoredox catalysis and photodynamic therapy, they are being developed in surpri
269 scular endothelial growth factor injections, photodynamic therapy, topical dorzolamide, oral dosing o
270 rcumvent the limitations of chemotherapy and photodynamic therapy, we have engineered a robust and sm
271 s as photosensitizers for oxygen sensing and photodynamic therapy, we investigated the potential beta
272           Verteporfin (VP) was first used in Photodynamic therapy, where a non-thermal laser light (6
273 mour cells with low or no PTEN expression to photodynamic therapy, which is based on the ability of p
274           Two main approaches are available: photodynamic therapy, which results in localized chemica
275 poxic tumours are a major problem for cancer photodynamic therapy.
276 umors without relapse by taking advantage of photodynamic therapy.
277  new venues to combat current limitations of photodynamic therapy.
278 ehicles to encapsulate a photosensitizer for photodynamic therapy.
279 ith multiple morphologies and application in photodynamic therapy.
280  oxaliplatin chemotherapy, radiotherapy, and photodynamic therapy.
281 itor, sensitizes xenotransplanted tumours to photodynamic therapy.
282 role of singlet oxygen and (1)O2 carriers in photodynamic therapy.
283  as effective and well-tolerated as daylight photodynamic therapy.
284 VEGF) interventions, dietary supplements, or photodynamic therapy.
285 econtouring, and antitumor and antimicrobial photodynamic therapy.
286 sensitizers for photocontrolled-delivery and photodynamic therapy.
287 erved between added reovirus before or after photodynamic therapy.
288 a history of choroidal neovascularization or photodynamic therapy.
289 orescence probes, as well as sensitizers for photodynamic therapy.
290 al wastewater treatment, photochemistry, and photodynamic therapy.
291 oninvasive optical imaging, optogenetics and photodynamic therapy.
292 ancer-killing techniques of photothermal and photodynamic therapy.
293  Ir1-HSA are highly favorable properties for photodynamic therapy.
294 enhanced imaging, or phototoxic for improved photodynamic therapy.
295 ong candidate photosensitizer for anticancer photodynamic therapy.
296                                          The photodynamic treatment of 3T3, HeLa, SK-MEL-28, and HCT
297                 The subcellular changes upon photodynamic treatment of the HeLa cells indicated that
298                In antibacterial practices by photodynamic treatment, bacteria are incubated with phot
299 tSerpin1 repressed cell death, only under AO photodynamic treatment.
300                  Global fold, stability, and photodynamics were analyzed in detergent by CD, stationa

 
Page Top